Veru Inc.

VERU Healthcare Biotechnology

In the quarter to June 2026, EPS grew 40.0% and free cash flow was flat, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three; insiders bought in the last twelve months.

2.30 0.14 −5.74%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
5/9
Altman Z
−5.84
Beneish M
−3.38
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.43 5.16 6.19 4.42
Net Debt/EBITDA
(15.33) 6.56 4.28 3.36
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.37) (0.30) (0.39) (0.24)
Book value per Share
1.25 1.83 1.51 1.23
Free Cash Flow
(5.49) (6.17) (8.91) (5.47)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates